La chaîne d'options affiche les données clés des options sur actions de Centerra Gold à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Centerra Gold..

Centerra Gold (NYSE:CGAU) Stock, Chaîne d'Options

Centerra Gold

Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets world-wide. The company reportable operating segments are Oksut; Mount; and Milligan Molybdenum. It derives maximum revenue from Oksut segment. Geographically, it operates in Turkey, United States, Canada and Other.

Centerra Gold Inc

Trading Ideas

Ohmyhome Shares Resume Trade

Shares of Cameco Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>) soared on Monday, trading up over 11% at $67.29 by late morning. The move higher followed the company&#8217;s announcement of a substantial expected boost to its earnings from its equity stake in Westinghouse Electric Company.
What To Know: Cameco, which holds a 49% interest in Westinghouse, <a href="https://www.benzinga.com/pressreleases/25/06/b45825614/cameco-reports-expected-increase-in-its-share-of-westinghouse-2025-adjusted-ebitda">revealed</a> it anticipates an approximate $170 million increase in its share of Westinghouse&#8217;s adjusted EBITDA for the second quarter and full year of 2025. 
This positive financial revision is directly linked to Westinghouse&#8217;s role as a subcontractor in the construction of two new nuclear reactors at the Dukovany power plant in the Czech Republic.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45841062/rocket-lab-ast-spacemobile-shares-are-surging-monday-whats-fueling-the-move">Rocket Lab, AST SpaceMobile Shares Are Surging Monday: What&#8217;s Fueling The Move?</a>
In addition to the immediate EBITDA uplift in 2025, Cameco <a href="https://www.benzinga.com/pressreleases/25/06/b45825614/cameco-reports-expected-increase-in-its-share-of-westinghouse-2025-adjusted-ebitda">expects</a> long-term financial benefits for Westinghouse through the duration of the Dukovany project, including the provision of fuel fabrication services for both reactors for a specified period.
This development is a significant return on investment for Cameco and its partner, Brookfield Renewable Partners, which owns the remaining 51% of Westinghouse. Despite this one-time boost, the long-term outlook for Westinghouse&#8217;s compound annual growth rate for adjusted EBITDA is maintained at a steady 6% to 10% over the next five years. 
The news was met with strong investor confidence Monday morning, reflected in the heavy trading volume of over 9.5 million shares, double the 100-day average.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45838486/apples-wwdc-2025-kicks-off-today-whats-going-on">Apple&#8217;s WWDC 2025 Kicks Off Today: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy CCJ Stock</h2>
By now you're likely curious about how to participate in the market for Cameco &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CCJ has a 52-week high of $68.12 and a 52-week low of $35.00.
Image: AI Generated

News

Cameco (CCJ) Stock Surges 11% On Westinghouse Nuclear Deal: What's Going On?

Analyst Ratings

Live On CNBC, Stephanie Link Announces Sold The Home Depot, Inc.

WIIM

VVPR

VivoPower International shares are trading higher after the company announced the date for its special dividend distributions related to the Tembo transactions.

UBER

Live On CNBC, Stephanie Link Announces Bought Uber Technologies

REGN

Regeneron Pharmaceuticals shares are trading higher. A company executive reportedly said the 23andMe auction process was recently reopened and that the tariff situation is not "material" to the business.

Insider Trades

PLUG

Plug Power Form4 Filing Shows Paul B Middleton Bought 650,000 Shares At An Average Price Of $1.03/Share

Ohmyhome Shares Halted On Circuit Breaker To The Upside, Stock Now Up 92.2%

Morgan Stanley analyst Matthew Cost maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Overweight and raises the price target from $420 to $460.

Price Target

Morgan Stanley Maintains Overweight on AppLovin, Raises Price Target to $460

The U.S. Food and Drug Administration (FDA) sent a &#8220;refusal to file&#8221; letter to Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) on Monday regarding its AXS-14 (esreboxetine) treatment <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">of fibromyalgia</a>.
The FDA states that upon preliminary review, the New Drug Application (NDA) was not sufficiently complete to <a href="https://www.benzinga.com/pressreleases/25/06/g45832920/axsome-therapeutics-provides-update-on-the-new-drug-application-nda-for-axs-14-for-the-management-" target="_blank" rel="noreferrer noopener">permit a substantive review</a>.
Fibromyalgia is a chronic disorder characterized by widespread pain, fatigue, disturbed sleep, depression, and cognitive impairment.
Approximately 17 million Americans, 90% of whom are women, are estimated to suffer from fibromyalgia.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44587826/axsomes-solriamfetol-fails-primary-goal-in-depression-study-but-shows-improvements-in-associated-sleep-disorder" rel="noreferrer noopener">Axsome&#8217;s Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder</a>
Specifically, the FDA does not consider the second of the two placebo-controlled trials in the submission adequate and well-controlled because its primary endpoint was at 8 weeks, and it used a flexible-dose paradigm.
The FDA indicated that the first of the two placebo-controlled trials in the submission, which utilized a 12-week endpoint and a fixed-dose paradigm, is adequate and well-controlled.
The FDA did not raise any questions relating to the positive results of the studies, both of which met their primary endpoints.
To address the FDA&#8217;s feedback, Axsome will conduct an additional controlled trial. As requested by the FDA, this trial will use a fixed-dose paradigm and a 12-week primary endpoint. Axsome anticipates initiating this trial in the fourth quarter of 2025.
Axsome CEO Herriot Tabuteau said the company is &#8220;well positioned to initiate a new controlled trial that will incorporate the FDA&#8217;s feedback by the end of 2025.&#8221;
While the RTF is disappointing, William Blair had ascribed only $3.38 for the AXS-14 fibromyalgia program to total $199.98 sum-of-the-parts fair value in the model.
With the requirement for an additional study, analyst Myles Minter has delayed the launch of AXS-14 in the model to the second half of 2028 and now ascribes $1.89 for the program to the fair value.
Investor focus remains on the Alzheimer's disease agitation (AD-A), which is on track for the third quarter of 2025.
After talking with the company's management, William Blair said they believe the recent Refusal to File (RTF) is limited to the Division of Anesthesiology, Addiction Medicine, and Pain Medicine and the fibromyalgia program.
It should not impact the separate submission for AXS-05 in Alzheimer's disease agitation, which will go through the Psychiatry division in Q3 2025. 
The firm added that getting a PDUFA date for this application, supported by the ADVANCE and ACCORD studies, and possibly receiving priority review due to its breakthrough therapy status, would be a key milestone and help reduce concerns about FDA-related delays caused by its internal restructuring.
Price Action: AXSM stock is down 0.60% at $111.24 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/02/43790716/axsomes-axs-05-in-alzheimers-agitation-could-be-billion-dollar-opportunity-says-analyst" target="_blank" rel="noreferrer noopener">Axsome&#8217;s AXS-05 In Alzheimer&#8217;s Agitation Could Be Billion Dollar Opportunity, Says Analyst</a></li>
</ul>
Image: Shutterstock

Analyst Color

Biotech

Health Care

General

AXSM

FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required

Morgan Stanley analyst John Glass downgrades McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) from Overweight to Equal-Weight and lowers the price target from $329 to $324.

Downgrades

Morgan Stanley Downgrades McDonald's to Equal-Weight, Lowers Price Target to $324

Academy Sports and Outdoors, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) will release its first-quarter financial results before the <a href="https://www.benzinga.com/quote/ASO">opening bell on Tuesday, June 10.</a>
Analysts expect the Katy, Texas-based company to report quarterly earnings at 89 cents per share, down from $1.08 per share in the year-ago period. Academy Sports and Outdoors projects quarterly revenue of $1.37 billion, compared to $1.36 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On June 6, Academy Sports and Outdoors declared a quarterly cash dividend of 13 cents per share.
Academy Sports and Outdoors shares gained 2% to trade at $44.31 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/aso/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Citigroup analyst Paul Lejuez maintained a Buy rating and cut the price target from $60 to $55 on June 4, 2025. This analyst has an accuracy rate of 64%.</li>
<li>UBS analyst Michael Lasser maintained a Neutral rating and slashed the price target from $54 to $48 on June 4, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Wells Fargo analyst Ike Boruchow maintained an Equal-Weight rating and raised the price target from $38 to $43 on May 14, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Evercore ISI Group analyst Greg Melich maintained an In-Line rating and cut the price target from $54 to $53 on April 1, 2025. This analyst has an accuracy rate of 81%.</li>
<li>JP Morgan analyst Christopher Horvers maintained a Neutral rating and raised the price target from $52 to $54 on March 21, 2025. This analyst has an accuracy rate of 71%</li>
</ul>
Considering buying ASO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/ASO/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="407" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09123435/image-121-1024x407.png" alt="" class="wp-image-943539" style="width:577px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09123435/image-121-1024x407.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09123435/image-121-300x119.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09123435/image-121-768x305.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09123435/image-121.png 1501w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/45835438/top-3-financial-stocks-that-may-collapse-in-june">Top 3 Financial Stocks That May Collapse In June</a> </li>
</ul>
Photo via Shutterstock

Markets

Top Wall Street Forecasters Revamp Academy Sports and Outdoors Expectations Ahead Of Q1 Earnings

Morgan Stanley analyst Erin Wright initiates coverage on Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Overweight rating and announces Price Target of $364.

Initiation

Morgan Stanley Initiates Coverage On Molina Healthcare with Overweight Rating, Announces Price Target of $364

Morgan Stanley analyst Ricky Goldwasser initiates coverage on Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight rating and announces Price Target of $70.

Morgan Stanley Initiates Coverage On Centene with Overweight Rating, Announces Price Target of $70

NCPL

Netcapital shares are trading higher following the announcement that its portfolio company, Zelgor, has completed the acquisition of Mixie.

Morgan Stanley analyst Alexandra Steiger downgrades Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) from Overweight to Equal-Weight and lowers the price target from $346 to $280.

LULU

Morgan Stanley Downgrades Lululemon Athletica to Equal-Weight, Lowers Price Target to $280

SCHW

The Schwab Trading Activity Index Decreased To 39.68 In May, Down From Its Score Of 41.18 In April

Morgan Stanley analyst Dara Mohsenian reiterates Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) with a Overweight and maintains $81 price target.

Reiteration

Morgan Stanley Reiterates Overweight on Coca-Cola, Maintains $81 Price Target

Real estate investor Grant Cardone has navigated multiple economic downturns and can spot trends before most investors notice. He's been highlighting the growing trend of <a href="https://www.tiktok.com/@grantcardone/video/7512161619372166430?lang=en">renting over owning property</a> and explained some of the factors that have led to this change.
"Many people don't want to commit to 30 years. They're on the move," Cardone said.
Cardone mentioned housing prices, shortcomings of the Biden administration, and other details when painting the picture of America becoming a renter nation.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.</li>
</ul>
<h2 class="wp-block-heading">A Rolling Recession</h2>
Cardone believes we were in a recession during the Biden administration that wasn&#8217;t properly covered because the definition of a recession was changed. He stated that the U.S. experienced multiple back-to-back quarters of declining GDP, and job numbers only looked decent because 40%-45% of all added jobs were government jobs during the Biden administration.
Cardone mentioned this context since people are more likely to rent than buy during recessions. Mortgages become less accessible during recessions, and people don't have the money to keep up with living costs and save up for a down payment.
He also stated that some people are waiting for housing prices to go down. That's a common strategy during economic contractions, as people hope to buy at a lower price in a few months. Some potential home buyers have no problem with waiting for more affordable prices, and that has resulted in higher demand for the rental market.
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
<h2 class="wp-block-heading">More People Are Living Mobile Lifestyles</h2>
Cardone also mentioned that people are being more mobile instead of sticking to one place. This lifestyle makes it easier for people to get up and move to another city. Cardone is a fan of moving every once in a while. He moved from Louisiana to San Diego before moving to Los Angeles and finally Miami, where he currently resides.&nbsp;
Cardone believes you should relocate if you get too comfortable and seem to know everyone in the area. It seems like more people are following up on that advice by renting instead of buying.&nbsp;
Cardone specifically mentioned California and said that less than 16% of Californians own a home. He said that many of them cannot afford it due to high housing costs and the difficulty of qualifying for a mortgage. Getting a mortgage becomes even more difficult when houses are valued at millions of dollars.
See Also: Wall Street's Missing This AI Surgical Tech — You Don't Have To.<a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution"> Invest from $350.</a>
<h2 class="wp-block-heading">Housing Is Expensive</h2>
Although you're not building equity when you pay rent, housing isn't free either. Even after paying off the mortgage, you still have to contend with property taxes, repairs, and other homeownership costs. Cardone is on record saying that a primary residence is not a good investment.
Investors might generate higher returns if they put their money into the stock market instead of putting a down payment toward a primary residence. While it's advantageous to have a paid-off mortgage when you retire, your funds might grow faster if you put them to work in better investments.
The debate on buying vs. renting from an investment standpoint mainly applies to people who can afford housing. Cardone mentions that the Biden administration increased the country's debt by $8.4 trillion, and additional increases to the federal debt will make housing and all resources less affordable. Any additional debt causes the purchasing power of the U.S. dollar to decrease.
Read Next: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
Image: Shutterstock

Personal Finance

Grant Cardone Explains Why We Are Becoming A Renter Nation: 'Many People Don't Want To Commit To 30 Years. They're On The Move.'

NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) has outperformed the market over the past 5 years by 21.46% on an annualized basis producing an average annual return of 36.0%. Currently, NRG Energy has a market capitalization of $30.67 billion. 
Buying $100 In NRG: If an investor had bought $100 of NRG stock 5 years ago, it would be worth $464.05 today based on a price of $156.85 for NRG at the time of writing.
<h3>NRG Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749486612_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In NRG Energy 5 Years Ago Would Be Worth Today

Press Releases

Azimut Arranges Strategic Investment by Centerra Gold

Centerra Gold Announces Updated Mineral Resources at Kemess; Advancing Studies on the Project

Earnings

Centerra Gold Reports First Quarter 2025 Results; Approved up to $75 Million to Repurchase Shares in 2025; Announces Updated Mineral Resource at Kemess and Advancing Studies on the Project

Dividends

Centerra Gold Announces Quarterly Dividend of C$0.07 per Common Share

Centerra Gold Announces Results of 2025 Annual Meeting of Shareholders

Small Cap

Opinion

Gold's Return to $3,400 Spurs Sector Gains Amid $4,000 Forecasts

Grid Battery Metals Provides a CEO Update

Grid Battery Awards Contract for 2025 Exploration Program on its Copper-Gold Property to Hardline Exploration

Grid Battery Revises TD Media d/b/a Life Water Media Contract to Provide Media Services

Comments

Centerra Gold

Centerra Gold (CGAU) Options

Centerra Gold (NYSE:CGAU) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL